title: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.
abstract: OBJECTIVE
  Anaplastic thyroid cancer (ATC) is characterized by pleomorphic cells, has a poor prognosis, is highly devastating disease, and is not curable. No reliable biomarkers of metastatic potential, helpful for early diagnosis of ATC and therapeutic response have been found yet. Thrombospondin-1 (TSP-1) plays a fundamental role in cancer progression by regulating cell stromal cross-talk in the tumor microenvironment.
  
  
  OBJECTIVE
  Our goal was to understand whether TSP-1 could affect protein levels of its integrin receptors (e.g., ITGα3, α6, and β1) and cell morphology in BRAF(V600E)-ATC cells in vitro and in vivo.
  
  
  METHODS
  Anaplastic thyroid cancer-derived cell cultures and western blotting were used to assess integrin protein expression upon TSP-1 silencing. Immunohistochemistry was performed on orthotopic primary human ATC and metastatic ATC in lung tissue to compare TSP-1 and integrin protein expression levels.
  
  
  RESULTS
  TSP-1 knock-down down-regulates ITGα3, α6, and β1 in BRAF(V600E)-human ATC cells. BRAF(V600E)-ATC cells with TSP-1 knock-down were rounded compared to control cells, which displayed a spread morphology. TSP-1 knock-down also reduced TSP-1, ITGα3, α6, and β1 protein expression levels in vivo in the ATC microenvironment, which is enriched in stromal and inflammatory cells.
  
  
  CONCLUSIONS
  TSP-1 silencing causes changes in ITG levels and ATC cell morphology. The assessment of TSP-1 and ITG levels might contribute to earlier metastatic potential of BRAF(V600E)-positive aggressive thyroid cancers, and allow improved patient selection for clinical trials.
authors.affiliation: Human Thyroid Cancers Preclinical and Translational Research Laboratory, Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center (BIDMC) , Boston, MA , USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Duquette
authors.affiliation: Endocrine Service, Department of Pathology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Sadow
authors.affiliation: Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, Center for Vascular Biology Research (CVBR), Beth Israel Deaconess Medical Center (BIDMC) , Boston, MA , USA.
authors.forename: Jack
authors.initials: J
authors.lastname: Lawler
authors.affiliation: Human Thyroid Cancers Preclinical and Translational Research Laboratory, Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center (BIDMC) , Boston, MA , USA.
authors.forename: Carmelo
authors.initials: C
authors.lastname: Nucera
keywords: BRAFV600E; TSP-1; extracellular matrix; integrins; microenvironment; thyroid cancer